ARX-related epileptic encephalopathy

ARX-related epileptic encephalopathy is a severe neurological disorder caused by mutations in the ARX (Aristaless-Related Homeobox) gene located on the X chromosome. This gene plays a critical role in brain development, particularly in the migration and differentiation of interneurons in the cerebral cortex. Mutations in ARX lead to a spectrum of epileptic encephalopathies, including X-linked infantile spasms (also known as West syndrome when associated with ARX), Ohtahara syndrome, and other early-onset seizure disorders. The condition predominantly affects males, while carrier females may be unaffected or have milder manifestations. The hallmark features of ARX-related epileptic encephalopathy include early-onset seizures (often infantile spasms), severe to profound intellectual disability, and abnormal electroencephalographic (EEG) patterns. Affected individuals frequently exhibit dystonia, spasticity, and movement abnormalities. Brain imaging may reveal lissencephaly or other structural brain malformations in some cases, particularly with loss-of-function mutations. Additional features can include ambiguous genitalia in some affected males, reflecting the role of ARX in other developmental pathways. The central nervous system is the primary body system affected, though the musculoskeletal system may be secondarily impacted due to abnormal muscle tone and movement disorders. There is currently no cure for ARX-related epileptic encephalopathy. Treatment is primarily supportive and symptomatic, focusing on seizure management with antiepileptic medications, though seizures in this condition are often refractory (drug-resistant). Physical therapy, occupational therapy, and developmental support are important components of care. Hormonal therapy (such as ACTH) or vigabatrin may be used specifically for infantile spasms, though response rates vary. A multidisciplinary approach involving neurologists, geneticists, and rehabilitation specialists is essential for optimizing quality of life.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about ARX-related epileptic encephalopathy